South Africa’s wealthiest individual, Johann Rupert, has enjoyed a remarkable year, with his family’s fortune swelling by more than $5 billion amid robust performances across their key listed holdings, edging them nearer to the global top 100 billionaires.
As detailed on the Bloomberg Billionaires Index, the Rupert family has seen an addition of $5.3 billion—equivalent to R90 billion—to their wealth in 2025, elevating their total valuation to $18.9 billion (R320 billion). This positions them just shy of media tycoon Rupert Murdoch’s family fortune of $19.6 billion, reflecting the enduring strength of diversified investments in luxury and beyond.
Read – Rupert’s Remgro defies odds with 60% dividend increase
Central to this growth has been a strong rally in Richemont, the luxury goods powerhouse where the family maintains significant control; its shares have climbed nearly 30 per cent this year on the JSE, pushing the company’s market capitalisation close to R2 trillion. According to Euromonitor International, South Africa’s personal luxury goods sector is forecasted to expand by 15 per cent in 2025, buoyed by rising affluence and a shift towards experiential spending, which has underpinned demand for premium brands like those under Richemont’s umbrella.
The family’s investment vehicle Remgro has also advanced 16 per cent, achieving a R95 billion valuation, while Reinet rose 25 per cent to R109 billion. These gains come despite broader market volatility, highlighting the resilience of their portfolio spanning healthcare, beverages, insurance and infrastructure.
Earlier in the year, the dynasty severed its longstanding ties to tobacco, a cornerstone of their wealth since the 1940s when Anton Rupert established what became Rembrandt. Reinet divested its entire stake in British American Tobacco for £1.221 billion in January, marking a strategic pivot away from the industry that propelled their early expansion through mergers and listings.
Remgro’s diverse stakes include prominent names in healthcare like Mediclinic, brewing with Heineken, and financial services via OUTsurance, alongside energy and media interests. Recent restructuring saw Remgro assume full control of Mediclinic’s Southern African operations while ceding the Swiss arm to partners, streamlining focus amid evolving global healthcare dynamics.
Analysts at Allan Gray, including Jonty Fish and Malwande Nkonyane, remain optimistic about Remgro and Reinet, noting they trade at substantial discounts to net asset value that offer investors a margin of safety and potential upside. Developments such as the Vodacom-Maziv transaction, which valued assets above conservative estimates, and Heineken Beverages’ post-integration growth trajectory, suggest narrowing discounts ahead.
Read – Johann Rupert buys Italian company
For Reinet, the 33 per cent discount already prices in caution around private equity holdings, effectively valuing them at zero and creating opportunity if modest returns materialise. With cash reserves bolstered post-divestments, both vehicles are well-positioned for selective reinvestment or shareholder returns in a landscape favouring disciplined capital allocation.
This wealth expansion underscores the Rupert empire’s adaptability, from tobacco origins through luxury dominance to a broader conglomerate model. As global luxury resilience meets local market opportunities, the family’s trajectory continues to influence South Africa’s economic narrative, bridging historical foundations with forward-looking diversification.